Inpatient Smokers and LDCT Screening RCT
Current smokers who undergo annual low dose CT (LDCT) lung cancer screening and successfully quit smoking derive the greatest reduction in lung cancer mortality. Unfortunately, those at highest risk of lung cancer death- those with low socioeconomic status, blacks, and current smokers- are the same individuals that typically have reduced access to preventive healthcare such as smoking cessation services and screening tests. Furthermore, patients from underserved communities often have lower health literacy, less awareness of lung cancer screening, and a poor understanding of the trade-offs of LDCT screening. In 2015 the Center for Medicare and Medicaid Services began requiring (1) a shared decision-making (SDM) discussion including use of a patient decision aid and (2) smoking cessation counseling in order to receive reimbursement for LDCT screening. There is little guidance, however, to help healthcare systems implement this requirement. Furthermore, primary care physicians (PCPs) report time constraints, competing demands, and knowledge deficiencies as barriers to optimizing utilization of LDCT screening.
Checked against the public recordLast updated Jul 5, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Boston University
- Interventions being studied
- Behavioral: tobacco dependence/smoking cessation counseling; Behavioral: SDM; Other: Decision Aid; Other: LDCT brochure
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * hospitalized smokers at BMC meeting LDCT screening eligible criteria * males and females 55-80 years of age * ≥30-pack years smoking * current smoker * able to speak, read, and understand English * able and willing to participate and provide informed consent Exclusion Criteria: * severe co-morbidities expected to limit life expectancy or ability to tolerate surgical resection of a lung cancer, including patients requiring home oxygen therapy (an indicator of severe lung or heart disease), and patients with active cancer * patients who have already had LDCT screening in the past year
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Boston Medical CenterBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 5, 2019. Always confirm current availability with the study team.